Meeting
2018 ASCO Annual Meeting
A phase II trial of bevacizumab-GemAOD regimen for newly diagnosed extranodal NK/T cell lymphoma.
Authors
Zhiming Li
Sun Yat-Sen University Cancer Center, Guangzhou, China
Zhiming Li , Yu Wang , Jia Jia Huang , Tian Xiao Gao , Ke Wu , Fan Feng , Peng Sun , PanPan Liu , XiWen Bi , Yi Xia , Huilan Rao , Suxia Lin , Hanyu Wang , Wenqi Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT01921790
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7564)
DOI
10.1200/JCO.2018.36.15_suppl.7564
Abstract #
7564
Poster Bd #
201
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).
First Author: Andrea Cercek
Poster
2015 ASCO Annual Meeting
Randomized phase II crossover trial exploring the clinical benefit from targeting EGFR or VEGF with combination chemotherapy in patients with non-resectable biliary tract cancer.
First Author: Lars Henrik Jensen
Poster
2014 ASCO Annual Meeting
Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA).
First Author: Joseph N. Kerger
Poster
2022 ASCO Genitourinary Cancers Symposium
GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen.
First Author: Kenrick Ng